ABL class fusions, involving ABL1, ABL2, CSF1R, and PDGRFB, are present in approximately 10% of Ph-like B-ALL and are targetable with ABL tyrosine kinase inhibitors such as Dasatinib [14,32,83,88]. This evidence concerns the gene CSF1R and acute lymphoblastic leukemia.